PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12773033-0	2003	A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.	Hydantoins	24-33	aldo-keto reductase family 1 member B1	Rattus norvegicus	68-84	
16190759-0	2005	A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.	Hydantoins	43-52	aldo-keto reductase family 1 member B1	Rattus norvegicus	67-83	
16190759-1	2005	Discovery of a highly selective, potent, and safe non-carboxylic acid, non-hydantoin inhibitor of aldose reductase (AR) capable of potently blocking the excess glucose flux through the polyol pathway that prevails under diabetic conditions has been a long-standing challenge.	Hydantoins	75-84	aldo-keto reductase family 1 member B1	Rattus norvegicus	98-114	
16190759-1	2005	Discovery of a highly selective, potent, and safe non-carboxylic acid, non-hydantoin inhibitor of aldose reductase (AR) capable of potently blocking the excess glucose flux through the polyol pathway that prevails under diabetic conditions has been a long-standing challenge.	Hydantoins	75-84	aldo-keto reductase family 1 member B1	Rattus norvegicus	116-118	
12773033-1	2003	We report here on the discovery path that led to a structurally unprecedented non-hydantoin, non-carboxylic acid aldose reductase inhibitor, 24, which shows remarkably potent oral activity in normalizing elevated sorbitol levels and, more significantly, fructose levels in the sciatic nerve of chronically diabetic rats, with ED(90) values of 0.8 and 3 mpk, respectively.	Hydantoins	82-91	aldo-keto reductase family 1 member B1	Rattus norvegicus	113-129	
3115267-0	1987	Development of potent aldose reductase inhibitors having a hydantoin structure.	Hydantoins	59-68	aldo-keto reductase family 1 member B1	Rattus norvegicus	22-38	
10328974-6	1999	Aldose reductase inhibitors possessing either hydantoin or carboxylic acid groups prevented protein modification induced by naphthalene-1, 2-dihydrodiol but not protein modification induced by 1, 2-dihydroxynaphthalene or 1,2-naphthoquinone.	Hydantoins	46-55	aldo-keto reductase family 1 member B1	Rattus norvegicus	0-16	
1613744-2	1992	The hypothesis that clinical side effects of the aldose reductase inhibitor (ARI) sorbinil were related to its hydantoin ring led to a bioisosteric analysis and replacement of the hydantoin by a spiro hydroxy acetic acid moiety as in 40.	Hydantoins	111-120	aldo-keto reductase family 1 member B1	Rattus norvegicus	49-65	
1613744-2	1992	The hypothesis that clinical side effects of the aldose reductase inhibitor (ARI) sorbinil were related to its hydantoin ring led to a bioisosteric analysis and replacement of the hydantoin by a spiro hydroxy acetic acid moiety as in 40.	Hydantoins	180-189	aldo-keto reductase family 1 member B1	Rattus norvegicus	49-65	
2128352-0	1990	Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats.	Hydantoins	17-26	aldo-keto reductase family 1 member B1	Rattus norvegicus	44-60	
3115267-1	1987	Seventeen hydantoin derivatives were tested as inhibitors of aldose reductase, an enzyme believed to participate in the initiation of diabetic complications.	Hydantoins	10-19	aldo-keto reductase family 1 member B1	Rattus norvegicus	61-77